Ann: Trading Halt, page-10

A bit out of the blue - was expecting something related to asthma/copd.

Lots of research to do, however on first review of Dimerixs AGM presentation from November 2014 it look like an excellent space to be in as the NASDAQ competitors and comparators mentioned in the presentation have seen their market caps increase substantially since November 2014 :

Chemocentryx - per preso $203m, now = $314m
Trevena - per preso $144m, now = $272m
Retrophin - per preso $372m, now = $826m

http://dimerix.com/wp-content/uploads/Dimerix-AGM-Pres-Nov14-website.compressed1.pdf

Lots more research to do but let's see what is announced tomorrow.

Failed ASX IPO in July 2014? Their loss, our gain.